<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0484-7903</journal-id>
<journal-title><![CDATA[Revista mexicana de anestesiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. anestesiol.]]></abbrev-journal-title>
<issn>0484-7903</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Anestesiología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0484-79032022000200107</article-id>
<article-id pub-id-type="doi">10.35366/103885</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tratamiento del dolor agudo por lesión traumática en pacientes con adicciones]]></article-title>
<article-title xml:lang="en"><![CDATA[Treatment of acute pain from traumatic injury in patients with addictions]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vélez-Tovar]]></surname>
<given-names><![CDATA[Luisa Fernanda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cruz-Nocelo]]></surname>
<given-names><![CDATA[Evelyn Judith]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Serratos-Vázquez]]></surname>
<given-names><![CDATA[María Concepción]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Zúñiga-Carmona]]></surname>
<given-names><![CDATA[Víctor Hugo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Federico Lleras Acosta Clinidol Servicio de Anestesiología]]></institution>
<addr-line><![CDATA[Ibagué ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Mexicano del Seguro Social UMAE del Hospital de Traumatología y Ortopedia «Dr. Victorio de la Fuente Narváez» Centro Interdisciplinario del Estudio y Tratamiento del Dolor y Cuidados Paliativos]]></institution>
<addr-line><![CDATA[ Ciudad de México]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>45</volume>
<numero>2</numero>
<fpage>107</fpage>
<lpage>113</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0484-79032022000200107&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0484-79032022000200107&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0484-79032022000200107&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  Las guías actuales para el manejo del dolor en pacientes con adicciones no contemplan el tratamiento del dolor agudo.  Objetivo:  Describir los esquemas de tratamiento analgésico y la dosis promedio de opioide requerida para control del dolor agudo en pacientes consumidores de sustancias psicoactivas hospitalizados en un Servicio de Traumatología.  Material y métodos:  Se realizó un estudio descriptivo, retrospectivo y transversal a través de la revisión de expedientes de pacientes con lesión traumática y antecedente de consumo de sustancias que fueron tratados bajo un esquema de analgesia multimodal.  Resultados:  Se incluyeron 75 pacientes con edad promedio de 32 (± 9.6) años. El opioide indicado con mayor frecuencia fue la buprenorfina en 48% (dosis media 644 &#956;g/24h), seguida de la morfina en 28% (dosis media 20 mg/24h) y tramadol en 24% de los pacientes (dosis media 195 mg/24h). No hubo diferencia estadísticamente significativa (p &lt; 0.05) en el control del dolor entre los tres grupos, excepto que la intensidad del dolor en el grupo de la morfina fue mayor a las 24 horas.  Conclusión:  Los pacientes tratados con buprenorfina tuvieron mejor control del dolor en comparación con el grupo de morfina, aunque requirieron dosis 40% mayores a las recomendadas para pacientes con trauma.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  Current guidelines for pain management in addiction patients do not address acute pain care.  Objective:  To describe the analgesic treatment schemes and the average dose of opioid required for the control of acute pain in psychoactive substance-using patients hospitalized in a trauma department.  Material and methods:  A descriptive, retrospective, and cross-sectional study was carried out by reviewing the records of patients with traumatic injury and a history of substance use who were treated under a multimodal analgesia scheme.  Results:  75 patients with a mean age of 32 (± 9.6) years were included. The most frequently prescribed opioid was buprenorphine in 48% (mean dose 644 µg/24h), followed by morphine in 28% (mean dose 20 mg/24h) and tramadol in 24% of patients (mean dose 195 mg/24h). There was not statistically significant difference (p &lt; 0.05) in pain control between the three groups, except that the intensity of pain in the morphine group was greater at 24 hours.  Conclusion:  The patients treated with buprenorphine had better pain control compared to the morphine group, although doses 40% higher than those recommended for trauma patients were required.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Trastornos relacionados con sustancias]]></kwd>
<kwd lng="es"><![CDATA[dolor agudo]]></kwd>
<kwd lng="es"><![CDATA[analgesia]]></kwd>
<kwd lng="es"><![CDATA[heridas y traumatismos]]></kwd>
<kwd lng="en"><![CDATA[Substance-related disorders]]></kwd>
<kwd lng="en"><![CDATA[acute pain]]></kwd>
<kwd lng="en"><![CDATA[analgesia]]></kwd>
<kwd lng="en"><![CDATA[wounds and injuries]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<source><![CDATA[World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Villatoro-Velázquez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Reséndiz Escobar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mujica Salazar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Encuesta Nacional de Consumo de Drogas, Alcohol y Tabaco 2016-2017: Reporte de Drogas]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>CONADIC</collab>
<source><![CDATA[Informe sobre la situación de la Salud Mental y el Consumo de Sustancias Psicoactivas en México]]></source>
<year>2021</year>
<publisher-name><![CDATA[Observatorio Mexicano de Salud Mental y Consumo de Sustancias Psicoactivas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<collab>Cámara de diputados</collab>
<source><![CDATA[Consumo excesivo de alcohol, principal causa de muerte y discapacidad; mata a más personas que el VIH/SIDA. Boletín N°. 5480]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Covarrubias-Gómez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Betancourt-Sandoval]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[González-García]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adicciones, Anestesia y Dolor]]></article-title>
<source><![CDATA[Rev Mex Anest]]></source>
<year>2011</year>
<volume>34</volume>
<page-range>200-10</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beaulieu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anesthetic implications of recreational drug use]]></article-title>
<source><![CDATA[Can J Anaesth]]></source>
<year>2017</year>
<volume>64</volume>
<page-range>1236-64</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>American Association of Nurse Anesthetist</collab>
<source><![CDATA[Analgesia and anesthesia for substance use disorder patient]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
<name>
<surname><![CDATA[Hur]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kwak]]></surname>
<given-names><![CDATA[IS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improvement of burn pain management through routine pain monitoring and pain management protocol]]></article-title>
<source><![CDATA[Burns]]></source>
<year>2013</year>
<volume>39</volume>
<page-range>619-24</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahmadi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bazargan-Hejazi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Heidari Zadie]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pain management in trauma: A review study]]></article-title>
<source><![CDATA[J Inj Violence Res]]></source>
<year>2016</year>
<volume>8</volume>
<page-range>89&#8208;98</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serratos]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Manejo del dolor en paciente con trauma]]></article-title>
<source><![CDATA[Rev Mex Anest]]></source>
<year>2012</year>
<volume>35</volume>
<page-range>123-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khanna]]></surname>
<given-names><![CDATA[IK]]></given-names>
</name>
<name>
<surname><![CDATA[Pillarisetti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Buprenorphine - an attractive opioid with underutilized potential in treatment of chronic pain]]></article-title>
<source><![CDATA[J Pain Res]]></source>
<year>2015</year>
<volume>8</volume>
<page-range>859&#8208;870</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bart]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Maintenance medication for opiate addiction: the foundation of recovery]]></article-title>
<source><![CDATA[J Addict Dis]]></source>
<year>2012</year>
<volume>31</volume>
<page-range>207&#8208;225</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acuña]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento del dolor agudo en el paciente dependiente de sustancias]]></article-title>
<source><![CDATA[Rev Med Clin Condes]]></source>
<year>2014</year>
<volume>25</volume>
<page-range>664-73</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bates]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Schultheis]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Hanes]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Comprehensive Algorithm for Management of Neuropathic Pain]]></article-title>
<source><![CDATA[Pain Med]]></source>
<year>2019</year>
<volume>20</volume>
<page-range>S2&#8208;S12</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bravo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mico]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Berrocoso]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Discovery and development of tramadol for the treatment of pain]]></article-title>
<source><![CDATA[Expert Opin Drug Discov]]></source>
<year>2017</year>
<volume>12</volume>
<page-range>1281&#8208;1291</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vadivelu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Singh-Gill]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kodumudi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Practical guide to the management of acute and chronic pain in the presence of drug tolerance for the healthcare practitioner]]></article-title>
<source><![CDATA[Ochsner J]]></source>
<year>2014</year>
<volume>14</volume>
<page-range>426&#8208;433</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vadivelu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lumermann]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pain Control in the Presence of Drug Addiction]]></article-title>
<source><![CDATA[Curr Pain Headache Rep]]></source>
<year>2016</year>
<volume>20</volume>
<page-range>35</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
